Carcinogenicity assessment of lonidamine by dietary administration to Sprague-Dawley rats.
Following chronic dietary administration of 20, 60 and 180 mg/kg per day of lonidamine for 2 years to groups of Sprague-Dawley rats, treatment-related non-tumour findings seen microscopically included the following: atrophy of the testis with associated changes in epididymis and pituitary at all dosages; neuropathy in the sciatic nerve accompanied by skeletal muscle atrophy which was dose-related, particularly in male animals. Neither the incidence of tumour-bearing animals, nor the spectrum of tumours seen, was significantly changed. In the females given 180 mg/kg per day an overall reduction in tumour incidence was noted, which was reflected in a significant reduction (P < 0.001) in mammary tumours.
Patton
D S
DS
Hazleton UK, Harrogate.
Heywood
R
R
Barcellona
P S
PS
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004822:Epididymis / Q000187:drug effects; D005260:Female; D007191:Indazoles / Q000008:administration & dosage / Q000633:toxicity*; D008297:Male; D008321:Mammary Glands, Animal / Q000187:drug effects; D009374:Neoplasms, Experimental / Q000139:chemically induced*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012584:Sciatic Nerve / Q000187:drug effects; D013737:Testis / Q000187:drug effects
D000970:Antineoplastic Agents; D007191:Indazoles; C016371:lonidamine